Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 17c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.67), $0.17 better than the analyst estimate of ($0.84).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
• Blue Jay Gold gets OTCQB approval, to trade under JAYGF